Precision Immunotherapy in Axial SpA
Dr. Marina Magrey at the 2024 ACR Convergence meeting in Washington, DC.
Watch video →What's hot
View all perspectives
What's Hot
PsA: Impact of Sex
Dr. Arthur Kavanaugh discusses abstracts 1709 and 1471, along with a related seminar, presented at the 2024 ACR Convergence meeting in Washington, DC.
Watch video →
Cycling vs Switching after TNFi Failure in axSpA
Dr. Lihi Eder discusses abstract 0603, presented at the 2024 ACR Convergence meeting in Washington, DC.
Watch video →
A Fibroblast Renaissance
Dr. Andrea Fava at the 2024 ACR Convergence meeting in Washington, DC.
Watch video →
ICYMI: Sex related differences in PsA
Different factors are known to influence disease characteristics and outcomes in psoriatic arthritis (PsA).
Read more →
Palliative Care in Rheumatology
Dr. Jiha Lee talks with Dr. Shannon Herndon about abstracts 0204 and 1064, presented at the 2024 ACR Convergence meeting in Washington, DC.
Watch video →
Efficacy and Safety of Nipocalimab for Sjogren's Syndrome
Dr. Mike Putman reports on abstract 2527, Efficacy and Safety of Nipocalimab, an Anti-FcRn Monoclonal Antibody, in Primary Sjogren’s Disease: Results from a Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study (DAHLIAS), presented at the 2024 ACR Convergence meeting in Washington, DC.
Watch video →
ICYMI: Say Goodbye to Methotrexate in PMR?
For decades, glucocorticoids (GCs) have formed the backbone of polymyalgia rheumatica (PMR) management.
Read more →
Predicting Flares in Rheumatoid Arthritis
Dr. Jonathan Kay interviews Dr. John Isaacs about abstract 1349, presented at the 2024 ACR Convergence meeting in Washington, DC.
Watch video →
ICYMI: ORAL Surveillance - Is Statin Use the Problem/Solution?
The findings from ORAL Surveillance Study have been a dominant conversation at recent ACR Convergence, with the seminal findings and subsequent analyses a target of debate. Subsequent post-hoc analyses, follow-up studies, and claims data analyses have been used to further interpret the data, though a clear answer on safety is not certain. A study presented on Sunday reported on a new post-hoc analysis that provides new insights.
Read more →
Brian Jaros, MD Dr_Brian_MD
1 year 1 month ago
Cardiology is on!
Dr. Olin discusses Fibromuscular Dysplasia findings on imaging
Definite: string of beads and/or focal narrowing in right setting / location
Possible but nonspecific: dissection, ecstasia, aneurysm, and tortuously
@RheumNow #ACR24 https://t.co/Dr81KQfLSf
Bella Mehta bella_mehta
1 year 1 month ago
Why is there female predominance in #SLE - the extra X chromosome in females (XX) may not be inactivated properly- usually maintained by the long non-coding RNA #Xist
#ACR24 abst#2599 @RheumNow https://t.co/C9Qj5zSnpN
Antoni Chan MD (Prof) synovialjoints
1 year 1 month ago
Updated ACR guidelines on management of lupus nephritis (LN). Consider early biopsy. Focus on triple therapy in LN. From the panel discussion, Tacrolimus can be an alternative to CNI (Voclosporin) where there is no access to this. Manage comorbidities such as CV risk, bone… https://t.co/4R02YnRXDP https://t.co/3J7YcF5ucQ
Richard Conway RichardPAConway
1 year 1 month ago
Galloway et al. 117,050 individuals. VTE risk in RA consistently increased, irrespective of age, sex, BMI. Risk VTE 46% higher in RA! @RheumNow #ACR24 Abstr#1901 https://t.co/SQPcPiBeF2 https://t.co/BQkERUsGlL
Akhil Sood MD AkhilSoodMD
1 year 1 month ago
Abstract 1842: Off the shelf CAR T therapy
No lymphodepletion needed, delivering robust, targeted CD19+ B cell elimination in multiple in vitro assays
@RheumNow #ACR24
Mrinalini Dey DrMiniDey
1 year 1 month ago
Do pts w autoimmune disease (AID) respond differently to immune checkpoint inhibitors (ICI) & have different mortality or iRAE risk vs pts without AID?
Study of pts on ICI showed no significant difference in mortality in pts w & without pre-existing AID
Ab2532 #ACR24 @RheumNow https://t.co/suywDdGIB1
TheDaoIndex KDAO2011
1 year 1 month ago
Applying the guidelines to Cases- Dr M Dall’Era for a pt wit extrarenal lupus and active LN. #ACR24 @rheumnow https://t.co/lvOUWjEdEz
Brian Jaros, MD Dr_Brian_MD
1 year 1 month ago
Non-pharm tx in TAK - not something we always think about but…
Impressive effect of resistance exercise!!
Not just in symptoms but also inflammatory markers
Per Dr. Springer - even a stress ball could be enough for UE vascular health in these pt
@RheumNow #ACR24 https://t.co/3O46gobbMX
sheila RHEUMarampa
1 year 1 month ago
The updated 2024 ACR Guideline for Dx and Tx of #lupus nephritis is here!
Dr. Lisa Samaritano discusses the key recommendations 👇
For all pts: screen for LN, give HCQ and RAAS for pts with ⬆️ proteinuria
GCs in pts w/ LN class III/IV &/or V.
@Rheumnow #ACR24 @rheumarhyme https://t.co/wLVRGktR59
sheila RHEUMarampa
1 year 1 month ago
The overview for #lupus nephritis tx.
Triple therapy is preferred as first line due to:
1. RCTs (BLISS-LN & AURORA 1) showing improved outcomes w/ triple txs
2. Nephron loss happens with ongoing LN - time is kidney!
@RheumNow #ACR24 https://t.co/IQo3q3O1pt
Mike Putman EBRheum
1 year 1 month ago
Overall very reasonable, aligning ACR recs w/other guidance groups & updated data
Remember: guidelines are meant to be broken. Some patients can likely avoid pulse, others may need more steroid on the back end, biopsies are not benign
#ACR24 @RheumNow
Mike Putman EBRheum
1 year 1 month ago
Recommend "Triple Therapy" = Glucocorticoids + two other agents
Practically, that means MMF + belimumumab OR CNI for most pts
For the CYC afficionados, the lower-dose EUROLUPUS protocol is preferred
#ACR24 @RheumNow https://t.co/0gRISXSw0c
Mike Putman EBRheum
1 year 1 month ago
Happening now, new guidelines for mgmt. A few highlights:
Recommend prompt GC therapy, pulse x1-3d followed by oral pred (<0.5mg/kg/d) w/taper to <5mg by 6 months
Aligns with EULAR recs for a much-lower dose than most clinicians currently doing
#ACR24 @RheumNow https://t.co/B71i7FBYlQ
TheDaoIndex KDAO2011
1 year 1 month ago
Applying the #ACR24 #LupusNephritis: Case 2 by Dr M Dall’Era @RheumNow https://t.co/A7i103uHZT
Mike Putman EBRheum
1 year 1 month ago
Interesting! Study of pts w/ ANA(-) & dsDNA(+). 1 in 5 dx with APLS! Have others seen that?
I have been disgregarding this pattern, though some of that is related to my in-house assay (seems overly-sensitive) & my bias against overdiagnosis
#ACR24 @RheumNow Abstr#2391 https://t.co/FWgCjEwPDK
Poster Hall